All Helen Bright articles
-
NewsCentauri Therapeutics selects first clinical candidate for immunotherapeutic treatment of Gram-negative bacterial infections
Centauri Therapeutics Limited has announced the selection of its first clinical candidate in the ABX-01 programme. The compound is designed to target serious Gram-negative bacterial infections in the lung.